Key facts
- Nuwacell’s last known valuation is $202.5M (Jun 2022).
- It has raised $63.7M across 2 recorded rounds; the latest was Early Stage VC ($11.6M) in Apr 2025.
- Notable investors include Hefei Industry Investment Group, Legend Capital, Hefei Hi-Tech VC, GF Xinde Investment Management, Shanghai Jiao Tong University Foundation — 11 tracked in total.
- Status: Privately Held (backing).
Leadership
- Junying YuFounder & Chief Scientist
- Ying ZhangFounder & Chief Technology Officer
- Peng LinChief Financial Officer
- Luyan JiaoVice President, New Drug Development
Investors
11+- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Nuwacell
Funding rounds
2 roundsAbout Nuwacell
Developer of cell therapy products designed for Induced Pluripotent Stem Cells (iPSC). The company's products have systematically built a patent portfolio around iPSC technology applications, covering iPSC reprogramming, as well as induced differentiation, roduction processes and key raw materials of multiple functional cells, enabling patients with regenerative medicine and disease treatment.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- Hefei, Anhui, China
- Founded
- 2016
- Website
- nuwacell.com/
- Ownership
- Privately Held (backing)
Nuwacell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuwacell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuwacell in its N-PORT filings yet. We sweep new filings monthly.